Long-term clinical outcomes of 0.015 % tacrolimus HPβCD eye drops in ocular surface inflammatory disorders
The 0.015 % tacrolimus/HPβCD formulation proves efficacy, and safety over 12 months for the treatment of diverse ocular inflammatory conditions, delivering sustained clinical stability and patient-reported benefits with reduced steroid reliance.
Authors
- Rosario Touriño-Peralba (ORCID: https://orcid.org/0000-0003-0386-2362)
- Francisco J Otero-Espinar
- María Puente-Iglesias
- Miguel Gonzalez-Barcia
- Eva Torres-Sangiao
- Andrea Cuartero-Martínez
- María Jesús Giráldez
- Ana Castro-Balado
- María Teresa Rodríguez-Ares
- Irene Zarra-Ferro
- Eva Yebra-Pimentel
Institutions
- Universidade de Santiago de Compostela (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Instituto de Investigación Sanitaria de Santiago (ES)
- Complejo Hospitalario Universitario de Ferrol (ES)
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1016/j.ejps.2026.107459
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 0.00